Literature DB >> 28918577

Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population.

M Aravind Kumar1,2, Vineeta Singh3, Shaik Mohammad Naushad3, Uday Shanker4, M Lakshmi Narasu4.   

Abstract

In the view of aggressive nature of Triple-Negative Breast cancer (TNBC) due to the lack of receptors (ER, PR, HER2) and high incidence of drug resistance associated with it, a case-control association study was conducted to identify the contributing genetic risk factors for Triple-negative breast cancer (TNBC). A total of 30 TNBC patients and 50 age and gender-matched controls of Indian origin were screened for 9,00,000 SNP markers using microarray-based SNP genotyping approach. The initial PLINK association analysis (p < 0.01, MAF 0.14-0.44, OR 10-24) identified 28 non-synonymous SNPs and one stop gain mutation in the exonic region as possible determinants of TNBC risk. All the 29 SNPs were annotated using ANNOVAR. The interactions between these markers were evaluated using Multifactor dimensionality reduction (MDR) analysis. The interactions were in the following order: exm408776 > exm1278309 > rs316389 > rs1651654 > rs635538 > exm1292477. Recursive partitioning analysis (RPA) was performed to construct decision tree useful in predicting TNBC risk. As shown in this analysis, rs1651654 and exm585172 SNPs are found to be determinants of TNBC risk. Artificial neural network model was used to generate the Receiver operating characteristic curves (ROC), which showed high sensitivity and specificity (AUC-0.94) of these markers. To conclude, among the 9,00,000 SNPs tested, CCDC42 exm1292477, ANXA3 exm408776, SASH1 exm585172 are found to be the most significant genetic predicting factors for TNBC. The interactions among exm408776, exm1278309, rs316389, rs1651654, rs635538, exm1292477 SNPs inflate the risk for TNBC further. Targeted analysis of these SNPs and genes alone also will have similar clinical utility in predicting TNBC.

Entities:  

Keywords:  Breast cancer; Microarray genotyping; Risk prediction models

Mesh:

Year:  2017        PMID: 28918577     DOI: 10.1007/s11010-017-3187-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  27 in total

1.  Predictive and prognostic molecular markers for cancer medicine.

Authors:  Sunali Mehta; Andrew Shelling; Anita Muthukaruppan; Annette Lasham; Cherie Blenkiron; George Laking; Cristin Print
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

Review 2.  Circulating and disseminated tumor cells in the management of breast cancer.

Authors:  Jeffrey S Ross; Elzbieta A Slodkowska
Journal:  Am J Clin Pathol       Date:  2009-08       Impact factor: 2.493

3.  Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.

Authors:  Xiaoyan Ren; Yifei Liu; Yumei Tao; Guoxiang Zhu; Meilan Pei; Jianguo Zhang; Jian Liu
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

Review 4.  Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.

Authors:  Leticia De Mattos-Arruda; Carlos Caldas
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

5.  Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.

Authors:  Gillian S Dite; Robert J MacInnis; Adrian Bickerstaffe; James G Dowty; Richard Allman; Carmel Apicella; Roger L Milne; Helen Tsimiklis; Kelly-Anne Phillips; Graham G Giles; Mary Beth Terry; Melissa C Southey; John L Hopper
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-16       Impact factor: 4.254

Review 6.  Breast cancer before age 40 years.

Authors:  Carey K Anders; Rebecca Johnson; Jennifer Litton; Marianne Phillips; Archie Bleyer
Journal:  Semin Oncol       Date:  2009-06       Impact factor: 4.929

7.  Association between body mass index and risk of breast cancer among females of north India.

Authors:  Mahavir Singh; Babita Jangra
Journal:  South Asian J Cancer       Date:  2013-07

8.  ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.

Authors:  Man Tong; Tsun-Ming Fung; Steve T Luk; Kai-Yu Ng; Terence K Lee; Chi-Ho Lin; Judy W Yam; Kwok Wah Chan; Fai Ng; Bo-Jian Zheng; Yun-Fei Yuan; Dan Xie; Chung-Mau Lo; Kwan Man; Xin-Yuan Guan; Stephanie Ma
Journal:  Stem Cell Reports       Date:  2015-06-18       Impact factor: 7.765

9.  Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth.

Authors:  Ke Wang; Jiansheng Li
Journal:  Oncotarget       Date:  2016-12-27

10.  Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios.

Authors:  Johan Staaf; Johan Vallon-Christersson; David Lindgren; Gunnar Juliusson; Richard Rosenquist; Mattias Höglund; Ake Borg; Markus Ringnér
Journal:  BMC Bioinformatics       Date:  2008-10-02       Impact factor: 3.169

View more
  3 in total

1.  Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.

Authors:  M Aravind Kumar; Shaik Mohammad Naushad; Narasimhulu Narasimgu; S Nagaraju Naik; Srilatha Kadali; Uday Shanker; M Lakshmi Narasu
Journal:  Mol Biol Rep       Date:  2018-08-22       Impact factor: 2.316

Review 2.  Composition and function of ciliary inner-dynein-arm subunits studied in Chlamydomonas reinhardtii.

Authors:  Ryosuke Yamamoto; Juyeon Hwang; Takashi Ishikawa; Takahide Kon; Winfield S Sale
Journal:  Cytoskeleton (Hoboken)       Date:  2021-04-28

3.  Regulation of Lipocalin-2 oncogene and its impact on gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia.

Authors:  Sabah Linjawi; Zuhoor AlGaithy; Samar Sindi; Norah Hamdi; Ayman Linjawi; Mona Alharbi
Journal:  Saudi Med J       Date:  2018-06       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.